Fusion Antibodies Plc ( (GB:FAB) ) has issued an announcement.
Fusion Antibodies plc has announced that its issued share capital consists of 113,318,140 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their interests in the company’s share capital under the FCA’s Disclosure Guidance and Transparency Rules. The announcement reflects the company’s commitment to transparency and provides stakeholders with essential data for financial decision-making.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is low due to significant financial challenges, including declining revenues and persistent losses. While technical analysis indicates potential support levels, the bearish momentum and unattractive valuation further weigh down the score. Positive corporate events provide some optimism for future growth, but the immediate financial health remains a primary concern.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a proprietary CDRxTM platform for antibody humanization and serves an international client base, including eight of the top 10 global pharmaceutical companies.
YTD Price Performance: -4.26%
Average Trading Volume: 921,907
Technical Sentiment Signal: Hold
Current Market Cap: £7.65M
For detailed information about FAB stock, go to TipRanks’ Stock Analysis page.